INDV Indivior PLC Ordinary Shares PHARMACEUTICAL PREPARATIONS Best Pharmaceutical Stocks 2026 →

Indivior PLC Ordinary Shares (INDV) Stock: Buy, Sell, or Hold?

$36.28
+0.91 (+2.57%) ▲
5d: +4.98% 30d: +1.6% 90d: -0.6%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (23%)
Quality Score
50/100
Position
EXTENDED
30-Day Fair Range
$34.08 – $35.94
Position: EXTENDED
Forward P/E & Valuation
8.1x CHEAP
vs 9.5x historical avg
Wall Street Target
$49.50
+36.4% upside
Options IV & Volume
100th pct IV
HIGH volume confirmation
Support / Resistance
$33.80 / $37.02
Trend: Strong Uptrend
💡Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: INDV shows conflicting indicators. Wait for confirmation before entering.

Get Alerted When INDV Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$49.75
Based on 3.1% avg growth
INTRINSIC VALUE TODAY
$30.89
Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.5x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: INDV is currently trading at $36.28, which is considered extended relative to its 30-day fair value range of $34.08 to $35.94. From a valuation perspective, the stock is trading at a discount (Forward PE: 8.1) compared to its historical average (9.5). Remarkably, the market is currently pricing in an annual earnings decline of 5.4% over the next few years. This pessimistic expectation contrasts with the company's recent 239.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.

Technical Outlook: Technically, INDV is in a strong uptrend. The price is approaching resistance at $37.02. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.

Market Sentiment: INDV scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $49.50 (+36.4%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position EXTENDED
Historical Trading Range $34.08 - $35.94
Company Quality Score 50/100 (HOLD)
Options IV Signal 100th percentile (EVENT RISK)
Volume Confirmation HIGH
Confidence Score 23.1%

Trading Range & Key Levels

30-Day Trading Range $34.08 - $35.94
Current vs Trading Range EXTENDED
Expected Move (7 Days) ±$9.13 (25.2%)
Support Level $33.80
Resistance Level $37.02
Current Trend Strong Uptrend
Technical data as of Nov 2, 2026

Protect Your Profits

Holding INDV? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

Quantitative Signal Breakdown

  • BEARISH: Price extended above range
  • BEARISH: Options expensive (IV 100th percentile)
  • BEARISH: Weak technical setup (38/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 36.4% below Wall St target ($49.50)
  • WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market

Fundamental Context

Forward P/E (Next Year Est.) 8.05
Wall Street Target $49.50 (+36.4%)
Revenue Growth (YoY) 13.4%
Earnings Growth (YoY) 239.4%
Profit Margin 32.8%
Valuation Discount vs History -5.4% cheaper
PE vs Historical 8.1 vs 9.5 CHEAP
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -5.4% (market-implied from PE analysis)
1-Year Target $34.32 (-5%)
2-Year Target $32.47 (-11%)
3-Year Target $30.71 (-15%)
3-Yr Target (if PE normalizes) (PE: 8→10) $36.25 (0%)
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 19.9, Growth: 2.1%) $95.22 (+163%)
Base: (SPY PE: 8.0, Growth: 2.1%) $38.60 (+6%)
Bear: (PE: 6.8, Growth: 2.1%) $32.81 (-10%)
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.0 to 9.5
Stabilization Target: $42.82 (+18.0%)
PE Expansion Potential: +18.0%
Share INDV Analysis

Share this live INDV analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.

bloggers & journalists: you are free to use our charts with attribution.

Reddit & Retail Trader Sentiment (INDV)

Bullish 2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Oct 29, 2026
Daily AI digest
AI Retail Discussion Summary: Huron Consulting Group is set to join the S&P SmallCap 600 instead of Supernus Pharmaceuticals, effective November 3, due to Indivior Pharmaceuticals' acquisition of Supernus Pharmaceuticals.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams. View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 1:29 PM ET
Data refreshes hourly during market hours. Next update: 2:29 PM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for INDV.

Create Free Account

Already have an account? Log In

Top Rated Drug Manufacturers - Specialty & Generic Stocks

Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
NBIX
Neurocrine Biosciences I…
STRONG BUY
29 analysts
$208 23 SELL
ALKS
Alkermes Plc
STRONG BUY
20 analysts
$58 41 HOLD
AQST
Aquestive Therapeutics I…
STRONG BUY
9 analysts
$9 62 BUY
TEVA
Teva Pharma Industries L…
STRONG BUY
15 analysts
$49 36 SELL
HROW
Harrow Health Inc
STRONG BUY
9 analysts
$63 51 HOLD

Advanced INDV Option Strategies

Professional options setups generated by AI based on today's INDV price and gamma walls.

Iron Condor Bull Call Bear Put Collar

Explore More Analysis & Live Quant Tools

Part A: Deep-Dive INDV Research Pages
INDV Technical Chart INDV Price Prediction INDV Intrinsic Value DCF INDV Earnings Date INDV Investment Advisor INDV Fair Price Analyzer INDV Options Chain INDV Options Advisor INDV Options Analysis INDV Competitors
Part B: Tradestie Flagship Market Scanners
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals